Alembic Pharma gains after Q4 PAT climbs 29% YoY to Rs 203 cr
Mumbai, May 15 -- Revenue from operations grew 4.41% year on year (YoY) to Rs 1,847.72 crore in the quarter ended 31 March 2026.
Profit before tax (PBT) stood at Rs 118.62 crore in Q4 FY26, up 38.20% from Rs 191.95 crore recorded in the same quarter last year.
EBITDA pre R&D increased by 8% year-on-year to Rs 455 crore, while the pre R&D EBITDA margin stood at 25% during the period under review.
India Branded Business posted a 4% year-on-year growth, with revenue reaching Rs 568 crore in the quarter. The performance was supported by steady traction across key therapeutic areas, with gynaecology, gastroenterology, ophthalmology and animal healthcare segments delivering encouraging momentum during the period. The company also strengthene...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.